Anacura, a Ghent, Belgium-based firm providing medical and pharmaceutical analytical companies, acquired OHMX.bio, a Ghent College spin-off specialised in superior -omics expertise.
The quantity of the deal was not disclosed.
The acquisition expands the present anacura group actions at AnaBioTec and Labo Nuytinck in the direction of drug discovery and diagnostics analysis.
Established in 2019, and led by CEO and CSO Gerben Menschaert, as a Ghent College spin-off, OHMX.bio operates as a research design firm, specializing in -omics applied sciences for discovery and (pre)medical research. The corporate combines multi-omic applied sciences, resembling sequencing, together with superior bio-informatics to hurry up the invention course of and high quality management of biologics and superior remedy medicinal merchandise (ATMPs) such asmRNA vaccines and CAR-T cells.
Led by CEO Griet Nuytinck, Anacura is an unbiased laboratory group with greater than 250 dynamic staff based mostly in Evergem (Ghent) and Bruges. Energetic in varied areas of healthcare, Anacura operates daughter corporations AnaBioTec and Labo Nuytinck, which ship end-to-end analytical drug growth options for pharma and biotech purchasers, and lab companies for sufferers and healthcare suppliers, respectively.
FinSMEs
05/07/2024
